Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.

Sun Pharma and Samsung BioLogics have announced a strategic long-term manufacturing agreement for Tildrakizumab.

Dr TH Kim, CEO of Samsung BioLogics and Anil Kumar Jain, CEO of Sun Pharma at the Signing ceremony in Incheon Samsung BioLogics Headquarter.

The agreement was entered into by Sun Pharma's wholly-owned subsidiary and Samsung BioLogics. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. Filings for this novel investigational biologic has been accepted for review by the FDA (May 2017) and the European Medicines Agency (EMA) (March 2017). The agreement was signed at Samsung BioLogics' headquarter in Incheon, South Korea. The approximate value of the contract will be US$ 55.5 million, other financial details of the agreement are confidential.

Commenting on the development, Dr TH Kim, President and CEO of Samsung BioLogics said: "Samsung BioLogics is pleased to join hands with Sun Pharma and is looking forward to delivering best-in-class manufacturing services with global quality standards. Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global market."

Commenting on its agreement with Samsung BioLogics, Mr Kirti Ganorkar, Global Head - Portfolio Management & Business Development, Sun Pharma said: "Samsung BioLogics is a globally renowned CMO. Through this partnership we will leverage Samsung's manufacturing knowledge and world class quality systems to provide high quality products for the Tildrakizumab pipeline."